Despite promising clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable difficulty from managed care entities. These organizations are typically erecting barriers to coverage, including significant cost restrictions and prior authorization that hinder user opport… Read More